CC
AUPH icon

Centiva Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Centiva Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,000
Closed -$225K – 1765
2023
Q4 		$225K Buy
+25,000
New +$206K 0.01% 1362
2023
Q3 		– Sell
-30,000
Closed -$290K – 1713
2023
Q2 		$290K Buy
+30,000
New +$311K 0.01% 1133

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Centiva Capital's AUPH Position: Q3 2023 in Review

Centiva Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2023, closing a stake of 316 shares — an estimated $3.06K sold.

Centiva Capital first reported a position in AUPH in Q1 2021 and held it in 2 quarters. The position peaked at $131K in Q1 2021. 198 funds tracked by Wall St. Rank hold AUPH as of Q3 2023.

  • Centiva Capital reported no remaining Aurinia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Centiva Capital sold 316 Aurinia Pharmaceuticals shares in Q3 2023, an estimated $3.06K.
  • Centiva Capital first reported a position in Aurinia Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Centiva Capital's Aurinia Pharmaceuticals position peaked at $131K in Q1 2021.
  • 198 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2023.

Based on Centiva Capital's 13F filing for Q3 2023, filed 14 Nov 2023.